S&P Futures
3,857.00+12.00(+0.31%)Dow Futures
31,184.00+88.00(+0.28%)Nasdaq Futures
13,357.50+63.25(+0.48%)
Agile Therapeutics, Inc. (AGRX)
2.9900 +0.02 (0.67%)
Before hours: 6:24AM EST
Chart Events
Performance Outlook
| Previous Close | 2.8600 |
| Open | 2.8500 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 4000 |
| Day's Range | 2.8500 - 2.9900 |
| 52 Week Range | 1.3500 - 4.7650 |
| Volume | 1,285,723 |
| Avg. Volume | 914,688 |
| Market Cap | 260.172M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5130 |
| Earnings Date | Feb 18, 2021 - Feb 22, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 |
Fair Value
Related Research
- GlobeNewswire
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The fireside chat will be available for on-demand listening beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the Investors section of the Agile Therapeutics website at www.agiletherapeutics.com, under the Events & Presentations tab. The archived webcast will be available for 30 days.About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.Follow Agile on LinkedIn and Twitter: @AgileTher.Contact: Matt Riley Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com
- Simply Wall St.
Are Institutions Heavily Invested In Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Shares?
A look at the shareholders of Agile Therapeutics, Inc. ( NASDAQ:AGRX ) can tell us which group is most powerful...
- GlobeNewswire
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on Thursday, January 14, 2021, at 9:10 a.m. ET. A live webcast of the presentation will be available in the Events and Presentations section of the Agile Therapeutics Investor Relations page. The archived webcast will be available for 30 days.About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.Follow Agile on LinkedIn and Twitter: @AgileTher.Contact: Matt Riley Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com
